A5066896225- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- RNA Research and Splicing
- Estrogen and related hormone effects
- Hormonal and reproductive studies
- Ubiquitin and proteasome pathways
- Radiopharmaceutical Chemistry and Applications
- Cancer-related molecular mechanisms research
- Molecular Biology Techniques and Applications
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Genomics and Chromatin Dynamics
- Renal cell carcinoma treatment
- Cancer-related gene regulation
- Prostate Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Environmental Changes in China
- Ferroptosis and cancer prognosis
- Protein Degradation and Inhibitors
- Tannin, Tannase and Anticancer Activities
- MicroRNA in disease regulation
- Catalytic Cross-Coupling Reactions
- Mass Spectrometry Techniques and Applications
- Sexual Differentiation and Disorders
Harvard University
2014-2025
Zoucheng People's Hospital
2025
Beth Israel Deaconess Medical Center
2013-2024
Wuhan University of Science and Technology
2024
First Affiliated Hospital of Nanchang University
2023
Nanchang University
2023
Hadassah Medical Center
2013-2022
Guangdong Pharmaceutical University
2021
Guangxi Medical University
2020
Peking Union Medical College Hospital
2018
Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen deprivation therapy primary can be mediated by reactivation the receptor (AR). One important mechanism mediating this AR is intratumoral conversion weak adrenal androgens DHEA and androstenedione into ligands testosterone dihydrotestosterone. are synthesized adrenals through sequential actions cytochrome P450 enzymes CYP11A1 CYP17A1, so CYP17A1 inhibitors such as abiraterone effective therapies for CRPC....
Significance We report that enhancer RNAs (eRNAs), a class of long noncoding RNAs, participate in the androgen receptor (AR)-dependent looping complex enhances spatial communication distal enhancers and target promoters, leading to transcriptional activation events. Furthermore, our data show KLK3 eRNA (KLK3e) selectively gene expression AR-regulated genes, provide evidence for positive regulatory loop which AR-dependent transcription is modulated by an intermediate eRNA. These findings may...
Androgen receptors (ARs) are phosphorylated at multiple sites in response to ligand binding, but the kinases mediating AR phosphorylation and importance of these function have not been established. Here we show that cyclin-dependent kinase 1 (Cdk1) mediates Ser-81 increases protein expression, Cdk1 inhibitors decrease phosphorylation, transcriptional activity prostate cancer (PCa) cells. The decline expression mediated by Cdk inhibitor roscovitine was prevented proteosome inhibitors,...
It seems clear that androgen receptor (AR)-regulated expression of the TMPRSS2:ERG fusion gene plays an early role in prostate cancer (PC) development or progression, but extent to which is down-regulated response deprivation therapy (ADT) and whether AR reactivates castration-resistant PC (CRPC) have not been determined. We show ERG message levels fusion-positive CRPC are comparable with gene-positive primary PC, consistent conclusion reactivated by CRPC. To further assess initially ADT, we...
Lysine-Specific Demethylase 1 (LSD1, KDM1A) functions as a transcriptional corepressor through demethylation of histone 3 lysine 4 (H3K4) but has coactivator function on some genes mechanisms that are unclear. We show LSD1, interacting with CoREST, associates and coactivates androgen receptor (AR) large fraction androgen-stimulated genes. A subset these AR/LSD1-associated enhancer sites have threonine 6 phosphorylation (H3T6ph), further enriched for Significantly, despite its activity, LSD1...
Our previous findings indicated that androgen receptor (AR) phosphorylation at serine 81 is stimulated by the mitotic cyclin-dependent kinase 1 (CDK1). In this report, we extended our study and confirmed Ser-81 increases during mitosis, coincident with CDK1 activation. We further showed blocking cell cycle G1 or S phase did not disrupt androgen-induced AR-dependent transcription, consistent a recent report AR was phosphorylated activated transcriptional CDK9. To assess function of in...
Men with metastatic prostate cancer who are treated androgen deprivation therapies (ADT) usually relapse within 2 to 3 years disease that is termed castration-resistant (CRPC). To identify the mechanism drives these advanced tumors, paired-end RNA-sequencing (RNA-seq) was performed on a panel of CRPC bone marrow biopsy specimens. From this genome-wide approach, mutations were found in series genes relevance, including AR, NCOR1, KDM3A, KDM4A, CHD1, SETD5, SETD7, INPP4B, RASGRP3, RASA1,...
Although well characterized as a transcriptional activator that drives prostate cancer (PCa) growth, androgen receptor (AR) can function repressor, and high-level androgens suppress PCa proliferation. The molecular basis for this repression activity remains to be determined. Genes required DNA replication are highly enriched among androgen-repressed genes, AR is recruited the majority of these where it rapidly represses their transcription. This enhanced in cells expressing high levels...
Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of multiple genes including MYC, and supraphysiological androgen is effective some patients. Here, we show that this independent AR chromatin binding driven by coactivator redistribution, through conformation capture methods disruption the interaction between MYC super-enhancer within PCAT1 gene promoter. Conversely, deprivation vitro vivo increases expression. In parallel, global activity suppressed...
Androgens and the androgen receptor (AR) act in cells by modulating gene expression. Through microarray studies, we have identified Ets Variant Gene 1 (ETV1) as a novel androgen-regulated gene. Our data demonstrate that ETV1 mRNA protein are up-regulated response to ligand-activated AR androgen-dependent LNCaP cells, but there is no detectable expression normal prostate cells. The promoter induced androgens recruits context of chromatin. ETV1-regulated endogenous matrix metalloproteinase...
Abstract BACKGROUND We have previously identified seven miRs‐ miR‐221 , ‐222 ‐23b ‐27b ‐15a ‐16‐1 and ‐203 that are differentially expressed in the hormone sensitive LNCaP cell line resistant LNCaP‐abl hypothesized these miRs may characterize certain subtypes of human castration prostate cancer (CRPC). METHODS Functional studies culture systems been performed to determine effect alternated expression level on cellular response androgen treatment. To clinical relevance patterns miRs, we...
BackgroundLimited data exist on VTE risk and prophylaxis in Chinese inpatients. The Identification of Hospitalized Patients' Risk Profile for Venous Thromboembolism-2 (DissolVE-2), a nationwide, multicenter, cross-sectional study, was therefore designed to investigate prevalence risks evaluate implementation compliant with the latest guidelines (American College Chest Physicians [CHEST], 9th edition).MethodsAdults admitted (≥ 72 h) 60 urban, tertiary hospitals due acute medical conditions or...
Abstract MYC is a well characterized oncogenic transcription factor in prostate cancer, and CTCF the main architectural protein of three-dimensional genome organization. However, functional link between two master regulators has not been reported. In this study, we find that rewires cancer chromatin architecture by interacting with protein. Through combining H3K27ac, AR HiChIP profiles CRISPR deletion site upstream gene, show activation leads to profound changes CTCF-mediated looping....
Prostate-specific antigen (<i>PSA</i>) is highly overexpressed in prostate cancer. One important regulator of<i>PSA</i> expression the androgen receptor (AR), nuclear that mediates biological actions of androgens. AR able to up-regulate <i>PSA</i> by directly binding and activating promoter this gene. We provide evidence here activity repressed tumor suppressor protein p53. p53 appears exert its inhibition human (hAR) disrupting amino- carboxyl-terminal (N-to-C) interaction, which thought be...
Androgen receptor (AR) is phosphorylated at multiple sites in response to ligand binding, but the functional consequences and mechanisms regulating AR phosphorylation remain be established. We observed initially that okadaic acid, an inhibitor of major PPP family serine/threonine phosphatases PP2A protein phosphatase 1 (PP1), had cell type-dependent effects on expression. More specific inhibitors (fostriecin) PP1 (tautomycin siRNA against PP1α catalytic subunit) demonstrated 2A opposite...
Androgen receptor (AR) interacts with -catenin and can suppress its coactivation of T cell factor 4 (Tcf4) in prostate cancer (PCa) cells.Pin1 is a peptidyl-prolyl cis/trans isomerase that stabilizes by inhibiting binding to the adenomatous polyposis coli gene product subsequent glycogen synthase kinase 3 (GSK-3)-dependent degradation.Higher Pin1 expression primary PCa correlated disease recurrence, this study found was markedly increased metastatic PCa.Consistent result, transfected...
Muscle wasting is the hallmark of cancer cachexia and associated with poor quality life increased mortality. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, has important biological effects in treatment muscular dystrophy. To verify whether VPA could ameliorate muscle induced by cachexia, we explored role two cachectic mouse models [induced colon-26 (C26) adenocarcinoma or Lewis lung carcinoma (LLC)] atrophied C2C12 myotubes C26 cell conditioned medium (CCM) LLC (LCM)]. Our data...
Androgen receptor (AR) is the principal molecule in prostate cancer (PCa) etiology and therapy. AR re‐activation still remains a major challenge during treatment of castration‐resistant (CRPC) tumors that relapse after castration therapies. Recent reports have indicated enrichment Ser81‐phosphorylated (pS81) nucleus CRPC cells, CDK1 CDK9 as kinases phosphorylating at S81. In current study we showed pS81 preferentially localized both rapid biopsy metastatic samples PCa xenografts, nuclear...
A rhodium(III)-catalyzed C-H allylation of (hetero)arenes by using 2-methylidenetrimethylene carbonate as an efficient allylic source has been developed for the first time. Five different directing groups including oxime, N-nitroso, purine, pyridine, and pyrimidine were compatible, delivering various branched allylarenes bearing hydroxyl group in moderate to excellent yields.
Background: Elevated homocysteine (Hcy) levels have been linked to poorer outcomes in acute coronary syndrome. This study aimed assess the predictive value of elevated Hcy for major adverse cardiac events (MACE) patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous intervention (PCI). Methods: retrospective cohort included 183 STEMI who underwent PCI at a tertiary university hospital southern China from January 2020 December 2021. Laboratory values,...
<title>Abstract</title> The human genome encodes 19 adenosine and cytidine deaminase genes, classified as A-to-I versus C-to-U editors. editors have been widely identified a promising therapeutic target in various cancers. Conversely, the investigation into is relatively limited. This study evaluated RNA-editing genes prostate cancer (PCa). Notably, APOBEC3 are clustered terms of their chromosomal locations, transcriptional changes exhibit significant positive correlations both primary PCa...
Prostate cancers respond to treatments that suppress androgen receptor (AR) function, with bicalutamide, flutamide, and cyproterone acetate (CPA) being AR antagonists in clinical use. As CPA has substantial agonist activity, it was examined identify coactivator/corepressor interactions may mediate androgen-stimulated prostate cancer growth. The CPA-liganded coactivated by steroid coactivator-1 (SRC-1) but did not N-C terminal or recruit beta-catenin, indicating a nonagonist conformation....
Abstract Prostate cancers (PCa) that relapse after androgen deprivation therapies [castration-resistant PCa (CRPC)] express high levels of receptor (AR) and androgen-regulated genes, evidence from several groups indicates ErbB family tyrosine kinases [epidermal growth factor (EGF) (EGFR) ErbB2] may contribute to enhancing this AR activity. We found activation these with EGF heregulin-β1 rapidly (within 8 hours) decreased expression endogenous PSA in LNCaP cells. was similarly LAPC4 C4-2...
miRNA expression profiles are widely investigated in the major cancers, but their specific roles and functions cancers have not yet to be fully elucidated. In this study, were determined clear cell renal carcinomas (ccRCC) matched normal kidney tissues by using a microarray platform which covers total of 851 human miRNAs. Differential 74 miRNAs identified between ccRCC specimens adjacent noncancerous tissues, 30 significantly upregulated ccRCCs, other 44 downregulated (fold change ≥ 2, P <...